News • Women's health

Breast cancer treatment has evolved. Here’s where we are.

There is no “one size fits all approach” when it comes to treating breast cancer. The disease is made up of several subtypes, and ideally each type should be treated with therapies that target the unique underlying biological problems.

Photo
Associate professor of medicine, division of hematology and oncology at the David Geffen School of Medicine at UCLA and medical director of UCLA’s Jonsson Comprehensive Cancer Center Clinical Research Unit.

Fortunately, for the past 25 years, long-term survival and cure rates have significantly improved for women with breast cancer. This is due in large part to the development of drug therapies that target aggressive subtypes of breast cancer such as HER2-positive and ER positive breast cancers. Some of these life-prolonging and life-saving treatments, including Herceptin and IBRANCE, were developed at UCLA. Targeted therapies are now available for approximately 85 percent of women diagnosed with breast cancer.

Dr. Sara Hurvitz, associate professor of medicine, division of hematology and oncology at the David Geffen School of Medicine at UCLA and medical director of UCLA’s Jonsson Comprehensive Cancer Center Clinical Research Unit, says that despite these successes there is still work to do. One particularly aggressive subtype called triple negative breast cancer now comprises between 10 to 20 percent of all diagnosed breast cancers, and is challenging to treat.  Recent research focuses on identifying its biological underpinnings so that scientists can develop more effective and less toxic treatments.

For Breast Cancer Awareness Month, Hurvitz can discuss how breast cancer research has evolved and what types of targeted therapies are available to women with the disease.


Source: University of California, Los Angeles (UCLA), Health Sciences

09.10.2017

Related articles

Photo

Interview • AI, modern mammography, and more

Breast imaging breakthroughs presented at EUSOBI 2024

Minimally invasive surgical interventions, innovative imaging and the use of AI: At the upcoming EUSOBI congress in Lisbon, experts present and discuss the latest advances in breast imaging. We spoke…

Photo

News • Breast cancer detection

Decade of DBT: 10-year study shows benefits of tomosynthesis

Evidence of the superiority of tomosynthesis for breast cancer detection is stacking up, with new results from a 10-year study further demonstrating the 3D imaging technique's benefits.

Photo

News • Research on BRCA recurrence

Breastfeeding after breast cancer treatment is safe, studies find

Two international studies presented at the ESMO Congress 2024 show no increase in recurrence or new breast cancers in women who breastfeed after being treated for breast cancer.

Related products

Subscribe to Newsletter